Balance Sheet

Accounts Payables Assets Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Current Assets Current Deferred Tax Assets Current Deferred Tax Assets Current Taxes Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Income Statement

Others

Ratios

Dr Reddys Laboratories (RDY) Operating Leases (2025 - 2026)

Dr Reddys Laboratories has reported Operating Leases over the past 2 years, most recently at $133.5 million for Q1 2026.

For Q1 2026, Operating Leases rose 184.44% year-over-year to $133.5 million; the TTM value through Mar 2026 reached $133.5 million, up 184.44%, while the annual FY2026 figure was $133.5 million, 177.62% up from the prior year.
Operating Leases for Q1 2026 was $133.5 million at Dr Reddys Laboratories, up from $46.9 million in the prior quarter.
Over five years, Operating Leases peaked at $133.5 million in Q1 2026 and troughed at $46.9 million in Q1 2025.